Alan J Kivitz1, Stanley Cohen2, Edward Keystone3, Ronald F van Vollenhoven4, Boulos Haraoui5, Jeffrey Kaine6, Haiyun Fan7, Carol A Connell8, Eustratios Bananis9, Liza Takiya10, Roy Fleischmann2. 1. Altoona Center for Clinical Research, 175 Meadowbrook Lane, PO Box 1018, Duncansville, PA 16635, USA. 2. Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX 75231, USA. 3. Mount Sinai Hospital, 600 University Ave, Toronto, ON M5G 1X5, Canada. 4. Amsterdam Rheumatology and Immunology Center, 1007 MB Amsterdam, The Netherlands. 5. Institut de Rhumatologie de Montréal, 1551, rue Ontario Est, Montréal, QC H2L 1S6, Canada. 6. Sarasota Arthritis Research Center, 1945 Versailles St, Sarasota, FL 34239, USA. 7. Pfizer Inc, 500 Arcola Rd, F5352, Collegeville, PA 19426, USA. 8. Pfizer Inc, 558 Eastern Point Rd, Groton, CT 06340, USA. 9. Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA. 10. Pfizer Inc, 500 Arcola Rd, F5352, Collegeville, PA 19426, USA. Electronic address: liza.takiya@pfizer.com.
Abstract
OBJECTIVE: This post-hoc, pooled analysis of Phase 3 studies of tofacitinib examined the safety of tofacitinib 5 and 10 mg twice daily (BID) when used as monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis (RA). METHODS: Pooled data from six double-blind, randomized controlled Phase 3 studies of tofacitinib 5 and 10 mg BID in patients with RA were analyzed for safety and stratified by administration as monotherapy (ORAL Solo: NCT00814307 and ORAL Start: NCT01039688) or in combination with csDMARDs (ORAL Sync: NCT00856544, ORAL Standard: NCT00853385, ORAL Scan: NCT00847613, and ORAL Step: NCT00960440), and by glucocorticoid use at baseline. Safety assessments included incidence rates (IRs) for serious adverse events (SAEs), discontinuations due to AEs, serious infection events, and herpes zoster (HZ), and were evaluated throughout the duration of the Phase 3 studies. RESULTS: In total, 3881 patients were included in the safety analysis (monotherapy studies: n = 1380; combination therapy studies: n = 2501). IRs for selected AEs of interest were generally numerically lower in patients who received tofacitinib 5 and 10 mg BID as monotherapy than as combination therapy (SAEs: IR [range] 6.21-6.72 versus IR 10.17-13.46; discontinuations due to AEs: IR 5.53-6.18 versus IR 10.80-11.01; serious infections: IR 1.57-1.66 versus IR 3.39-3.56; HZ: IR 1.95-2.93 versus IR 4.37-4.99, respectively), irrespective of tofacitinib dose or glucocorticoid use. There were too few patients and events within the placebo group to fully evaluate effect between combination therapy and monotherapy. CONCLUSIONS:Safety profiles were generally similar between patients receiving monotherapy and combination therapy; however, selected safety events of interest, including HZ and serious infections, showed lower IRs with non-overlapping 95% confidence intervals for tofacitinib all monotherapy versus combination therapy. Tofacitinib monotherapy may, therefore, have fewer safety events compared with combination therapy, and have a favorable risk-benefit profile in patients with active RA who are intolerant to csDMARDs.
RCT Entities:
OBJECTIVE: This post-hoc, pooled analysis of Phase 3 studies of tofacitinib examined the safety of tofacitinib 5 and 10 mg twice daily (BID) when used as monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis (RA). METHODS: Pooled data from six double-blind, randomized controlled Phase 3 studies of tofacitinib 5 and 10 mg BID in patients with RA were analyzed for safety and stratified by administration as monotherapy (ORAL Solo: NCT00814307 and ORAL Start: NCT01039688) or in combination with csDMARDs (ORAL Sync: NCT00856544, ORAL Standard: NCT00853385, ORAL Scan: NCT00847613, and ORAL Step: NCT00960440), and by glucocorticoid use at baseline. Safety assessments included incidence rates (IRs) for serious adverse events (SAEs), discontinuations due to AEs, serious infection events, and herpes zoster (HZ), and were evaluated throughout the duration of the Phase 3 studies. RESULTS: In total, 3881 patients were included in the safety analysis (monotherapy studies: n = 1380; combination therapy studies: n = 2501). IRs for selected AEs of interest were generally numerically lower in patients who received tofacitinib 5 and 10 mg BID as monotherapy than as combination therapy (SAEs: IR [range] 6.21-6.72 versus IR 10.17-13.46; discontinuations due to AEs: IR 5.53-6.18 versus IR 10.80-11.01; serious infections: IR 1.57-1.66 versus IR 3.39-3.56; HZ: IR 1.95-2.93 versus IR 4.37-4.99, respectively), irrespective of tofacitinib dose or glucocorticoid use. There were too few patients and events within the placebo group to fully evaluate effect between combination therapy and monotherapy. CONCLUSIONS: Safety profiles were generally similar between patients receiving monotherapy and combination therapy; however, selected safety events of interest, including HZ and serious infections, showed lower IRs with non-overlapping 95% confidence intervals for tofacitinib all monotherapy versus combination therapy. Tofacitinib monotherapy may, therefore, have fewer safety events compared with combination therapy, and have a favorable risk-benefit profile in patients with active RA who are intolerant to csDMARDs.
Authors: Roy Fleischmann; Jürgen Wollenhaupt; Liza Takiya; Anna Maniccia; Kenneth Kwok; Lisy Wang; Ronald F van Vollenhoven Journal: RMD Open Date: 2017-12-18
Authors: William J Sandborn; Deanna D Nguyen; David T Beattie; Patrick Brassil; Whitney Krey; Jacky Woo; Eva Situ; Reuben Sana; Erik Sandvik; M Teresa Pulido-Rios; Raj Bhandari; Jonathan A Leighton; Ravi Ganeshappa; David L Boyle; Brihad Abhyankar; Melanie A Kleinschek; Richard A Graham; Julian Panes Journal: J Crohns Colitis Date: 2020-09-16 Impact factor: 9.071
Authors: Ara Dikranian; David Gold; Louis Bessette; Peter Nash; Valderilio F Azevedo; Lisy Wang; John Woolcott; Andrea B Shapiro; Annette Szumski; Dona Fleishaker; Jürgen Wollenhaupt Journal: Rheumatol Ther Date: 2021-12-17
Authors: Jose María Álvaro-Gracia; Jose Francisco García-Llorente; Mónica Valderrama; Susana Gomez; Maria Montoro Journal: Rheumatol Ther Date: 2020-11-27